My current primary research interests include statistical aspects of design, implementation and analysis of clinical trials; design and analysis of quality of life studies, and survival analysis. As one of the statisticians for the NRG Oncology I have been involved in design, analysis, and served as a primary statistician on clinical trials evaluating therapies for the prevention and treatment of breast and colorectal cancer.
BIOST2038: Foundations of Statistical Theory
BIOST 2043: Introduction to Statistical Theory I
BIOST 2044: Introduction to Statistical Theory II
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SKL, Brufsky A, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Breast Cancer Index and prediction of extended aromatase inhibitor therapy benefit in hormone receptor-postive breast cancer from the NRG Oncology/NSABP B-42 Trial. Clinical Cancer Research 2024; 30 (9), 1984-1991. PMID: 38376912
Ganz PA, Bandos H, Spanic T, Friedman S, Müller V, Kümmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song C, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t’Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brug`ere C, Friedlander M, Seok Lee K, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber JE, Geyer Jr CE, Tutt ANJ. Patient-Reported Outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2–negative early breast cancer. JCO 2024; 42 (11), 1288-1300. PMID: 38301187
Mamounas EP, Bandos H, Rastogi P, Lembersky BC, Jeong JH, Geyer Jr CE, Rastogi P, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Wade III JL, McCarron EC, Swain SM, Wolmark N. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. JNCI 2023; 115 (11), 1302-1309. PMID: 37184928
Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Res Treat. 2022 Jun;193(3):555-564. PMID: 35230585.
Ganz PA, Bandos H, Geyer CE Jr, Robidoux A, Paterson AHG, Polikoff J, Baez-Diaz L, Brufsky AM, Fehrenbacher L, Parsons AW, Ward PJ, Provencher L, Hamm JT, Stella PJ, Carolla RL, Margolese RG, Shibata HR, Perez EA, Wolmark N. Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Res Treat. 2022; Feb;192(1):153-161. PMID: 35112166
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, and Geyer, Jr CE. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021 384 (25):2394-2405. PMID 34081848
Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer Jr CE, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade III JL, McCarron EC, Paik S, Swain SM, Wickerham DL, and Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. 2019; 20: 88-99. PMID: 30509771
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL, III, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term effects of adjuvant chemotherapy on peripheral neuropathy in patients with early-stage breast cancer: Secondary analysis of NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018; 110(2).
Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated Peripheral Neuropathy in Patients with Early- Stage Breast Cancer: A Systematic Review of Long-Term Adverse Effects. J Natl Cancer Inst. 2018; 110 (2).
Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ. Results from NRG Oncology/NSABP protocol DMP-1: women’s decision-making in breast cancer risk reduction. Cancer Prevention Research. 2017; 10(11): 625-634.
Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong, JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL. Association of Polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2–positive breast cancer analysis of the NSABP B-31 trial. JAMA Oncology. 2017; 3(3):335-341.
Jatoi I, Bandos H, Jeong JH, Anderson WF, Romond EH, Mamounas EP, Wolmark N. Time-varying effects of breast cancer adjuvant systemic therapy. J Natl Cancer Inst 2015 108(1)
Klepin HD., Geiger AM., Bandos H., Costantino JP., Rapp SR., Sink KM., Lawrence JA., Atkinson HH., Espeland MA. Cognitive factors associated with adherence to oral anti-estrogen therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene Study. Cancer Prevention Research. 2014 Jan;7(1):161-168.
Danhauer SC, Legault C, Bandos H, Kidwell K, Costantino J, Vaughan L, Avis NE, Rapp S, Coker LH, Naughton M, Naylor C, Terracciano A, Shumaker S. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. Aging, neuropsychology and cognition: a journal on normal dysfunctional development, 2013; 20(5):532-52.
Jung S, Jeong JH, Bandos H. Regression on quantile residual life. Biometrics. 2009, 65: 1203-1212.
Fisher ER, Costantino JP, Leon ME, Bandos H, Palekar AS, Fisher B, Wolmark N. Pathobiology of small invasive breast cancer without metastases (T1a/b, N0, M0). National Surgical Adjuvant Breast and Bowel Project (NSABP). Protocol B-21. Cancer. 2007, November 1. 110(9): 1929-1936
